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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: The continued movement away from the treatment of individual cardiovascular (CV) 
risk factors to managing overall and lifetime CV risk is likely to have a signiﬁ  cant impact on 
slowing the rate of increase in cardiovascular disease (CVD). However, the management of 
CVD is currently far from optimal even in parts of the world with well-developed and well-
funded healthcare systems. Effective implementation of the knowledge, treatment guidelines, 
diagnostic tools, therapeutic interventions, and management programs that exist for CVD con-
tinues to evade us. A thorough understanding of the multifactorial nature of CVD is essential 
to its effective management. Improvements continue to be made to management guidelines, 
risk assessment tools, treatments, and care programs pertaining to CVD. Ultimately, however, 
preventing the epidemic of CVD will require a combination of both medical and public health 
approaches. In addition to improvements in the “high-risk” strategy, which forms the basis of 
current CVD management, an increase in the utilization of population-based management strate-
gies needs to be made to attempt to reduce the number of patients falling within the “at-risk” 
stratum for CVD. This review outlines how a comprehensive approach to CVD management 
might be achieved.
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Introduction
Cardiovascular disease (CVD) is one of the most prevalent and devastating health 
problems in the world and is responsible for approximately 30% of deaths worldwide 
(WHO 2005) which equates to about 16.6 million deaths (Figure 1). It is the leading 
cause of death in many developed countries and, by 2010, it is thought that CVD will 
be the leading cause of death in developing countries (WHO 2005). Furthermore, 
the mortality, ﬁ  nancial, and medical resource costs of CVD worldwide are huge and 
increasing.
Efforts are being extended to investigate ways to optimally manage risk factors 
for CVD and to improve medical interventions for the disease. In some countries 
these efforts have been rewarded with reductions in CVD mortality, as seen in most 
Northern, Southern, and Western European countries (Rayner 2000). An example of 
a successful community-based intervention strategy was started in the North Karelia 
province of Finland in 1972 (Puska 1988; Vartiainen et al 1994; Puska et al 1998). 
The interventions aimed to change target risk factors and health behaviors (serum 
cholesterol, blood pressure, smoking, diet) at the population level. In the early 1970s 
middle-aged Finnish men had the highest mortality from CVD in the world, but since 
this prevention program was started the mortality rate decreased dramatically; from 
1969–1971 to 1995 the age-standardized coronary heart disease (CHD) mortality (per 
100,000) decreased in North Karelia by 73% (Puska et al 1998).Vascular Health and Risk Management 2006:2(4) 465–475
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However, in many regions, reductions are not as impres-
sive or conversely the prevalence of CVD is rising. World-
wide increases in CVD events are anticipated because the 
disease remains uncontrolled on a global scale. There is, 
therefore, a critical need to ﬁ  nd ways to blunt the worldwide 
increase in CVD projected for forthcoming decades (Murray 
and Lopez 1997).
What may be surprising is that we already possess the 
knowledge and the tools to signiﬁ  cantly reduce the burden 
of CVD risk. However, effectively implementing the treat-
ment guidelines, diagnostic tools, therapeutic interventions, 
and management programs that exist for CVD somehow still 
manages to evade us. Among the reasons for this include the 
increasing number of people adopting lifestyles that are at 
odds with maintaining an acceptable CVD risk (WHO 2005; 
Chobanian et al 2003), elements of which may include poor 
diet, smoking, and physical inactivity. Furthermore, epidem-
ics of conditions related to these unhealthy lifestyles (eg, 
diabetes and obesity) are escalating, which further increases 
the rise in CVD. For example, it has been estimated that there 
are more than 1 billion overweight adults and more than 300 
million adults who are clinically obese (AHA 2003). Obe-
sity rates have dramatically increased (3 fold) in parts of 
North America, Eastern Europe, the Middle East, the Paciﬁ  c 
Islands, Australia, and China since 1980 (AHA 2003).
The prevalence of diabetes (which is closely linked with 
obesity) is also increasing rapidly. For example, the world-
wide prevalence of diabetes is expected to nearly double from 
2.8% in 2000 to 4.4% in 2030, a rise from 171 million to 366 
million people (Wild et al 2004). In the US, the prevalence 
of those diagnosed with diabetes has increased by 61% since 
1990 (Rosamond et al 2007). It is estimated that 20.8 mil-
lion Americans (7% of the population) now have diabetes 
(Rosamond et al 2007). Similarly, the prevalence of type 2 
diabetes has now reached epidemic levels in Asia (Yoon et al 
2006) with levels very similar to those in the US and Europe 
(approximately 7.8% in 2003). The highest rates in Europe are 
generally observed in countries of Central and Eastern Europe 
(International Diabetes Federation’s Diabetes Atlas). The ever 
increasing worldwide burden of diabetes will have a substantial 
impact on the occurrence of CVD. The recent INTERHEART 
study revealed that worldwide those with diabetes are 2.37 
times more likely to experience a myocardial infarction (MI) 
in comparison with those without diabetes (Yusuf et al 2004). 
Moreover, previous studies have demonstrated that diabetes 
is associated with a CV risk similar to that post-MI (Haffner 
et al 1998) and an equivalent risk to ageing 15 years (Booth 
et al 2006) (Table 1). Of note is the fact that diabetes has a far 
greater adverse impact on women, although women develop 
CHD at a later age, usually lagging behind men by about 
Figure 1 The mortal and morbid consequences of cardiovascular disease.
Source: aWorld Health Organization, 2005Vascular Health and Risk Management 2006:2(4) 465–475
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Managing cardiovascular risk in practice
10 years (Lerner and Kannel 1986), women with diabetes are 
up to 50% more likely to die from CHD compared with men 
with diabetes (Natarajan et al 2003; Huxley et al 2006).
The management of CVD is currently in a state of 
transformation. In the past, the management process has 
centered on the modiﬁ  cation of single risk factors, such as 
hypertension. However, there have been repeated calls to 
move away from this siloed approach (Ansell 2005; Giles et al 
2005; Jackson et al 2005; Mancia 2006) and many treatment 
guidelines now recommend simultaneously adopting lifestyle 
and therapeutic interventions targeted at multiple risk factors 
(De Backer et al 2003; Joint British Societies 2005). This 
change of perception promises to have a positive impact on 
the success of treatment for the disease. This review aims 
to demonstrate how the consideration of the multifactorial 
nature of CVD needs to become the cornerstone of how CVD 
is viewed, assessed, and ultimately managed.
Key points
–  CVD is responsible for approximately 30% of deaths 
worldwide.
–  The multifactorial nature of CVD needs to underpin 
management strategies for the disease.
–  To optimally manage CVD, therapeutic interventions 
need to target multiple risk factors.
Multifactorial nature of CVD
The numerous risk factors for CVD are usually catego-
rized based on whether they are modiﬁ  able or are non-
modiﬁ  able (Table 1). In addition, certain factors have been 
shown to be protective against the development of CVD, 
namely, daily consumption of fruit and vegetables, regular 
moderate alcohol consumption, and regular physical activ-
ity (McManus 2005). Evidence accumulated over the past 
30 years has consistently demonstrated that these risk factors 
are linked epidemiologically, clinically, and metabolically 
(Neaton and Wentworth 1992; Asmar et al 2001; Thomas 
et al 2002; Felmeden et al 2003; Greenland et al 2003; Bhatt 
et al 2006).
One of the most revolutionary ﬁ  ndings from epidemiologi-
cal data is that hypertension usually occurs in conjunction with 
other major risk factors for CVD, namely, glucose intoler-
ance, obesity, left ventricular hypertrophy, and dyslipidemia 
(Kannel 2000a, b; Asmar et al 2001; Greenland et al 2003; 
O’Meara et al 2004; Bhatt et al 2006).
This is thought to be because these factors are metaboli-
cally linked to hypertension, and could thus form a predispo-
sition to development of the condition (Reaven et al 1996). 
Findings from various studies, including the Framingham 
Heart Study have shown that CVD risk factor “clustering” 
occurs frequently in individuals (Kannel 2000a, b; Asmar et al 
Table 1 Major risk factors and protective factors for CVD
Category Factor Contribution to CVD
Modiﬁ  able risk factors Hypertension
Dyslipidemia
Cigarette smoking
Diabetes
Abdominal obesity
Excess alcohol
Sedentary lifestyle
Continuous relationship between BP level and CVD risk above 135/85 mmHg
Elevated total cholesterol and LDL cholesterol, as well as low levels of HDL cholesterol, 
confer CVD risk
Risk of CHD is 2–4 times higher in smokers than in non-smokers. Risk starts with any daily 
amount and declines progressively after tobacco use is discontinued. Exposure to smoke also 
confers risk.
Imposes a CV risk similar to myocardial infarction (Haffner et al 1998) and an equivalent risk 
to ageing 15 years (Booth et al 2006). Increases risk even when glucose levels are controlled
Major contributor to hypertension, dyslipidemia and diabetes mellitus. Male fat distribution 
associated with greater risk than female fat distribution
Raises blood pressure, causes heart failure and can lead to stroke.
Major contributor to hypertension, dyslipidemia and diabetes mellitus 
Non-modiﬁ  able risk 
factors
Increasing age
Male gender
Family history of premature
CVD 
Signiﬁ  cantly increases risk of CVD in men >45 years and in women >55 years of age
Men have a higher risk of CVD than women of the same age and have heart attacks at an 
earlier age than women
Increased risk in people with parents or siblings with history of CVD at a premature age 
(<55 years in male relative and <65 years in a female relative)
Protective factors Daily consumption of fruit    
and vegetables
Regular moderate alcohol 
consumption
Regular physical activity 
Lowers BP and increases HDL cholesterol levels
Risk is lower in people who drink moderate amounts (average 1 drink/day for women and 
2/day for men) than in non-drinkers
Lowers BP and increases HDL cholesterol levels
Abbreviations: BP, blood pressure; CVD, cardiovascular disease; HDL, high density lipoprotein.Vascular Health and Risk Management 2006:2(4) 465–475
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2001; Greenland et al 2003; O’Meara et al 2004; Bhatt et al 
2006). A cluster of 2 or more risk factors occurs in approxi-
mately half of hypertensive persons, a frequency twice that 
expected by chance (Kannel 2000a, b). Clusters of 3 or more 
risk factors occur at 4 times the expected rate (Kannel 2000a, 
b). In fact, only 10%–20% of cases of hypertension occur 
in the absence of other CVD risk factors (Kannel 2000a, b; 
Bhatt et al 2006), for example, in the Reduction of Athero-
thrombosis for Continued Health (REACH) registry, 90.3% 
of patients with hypertension had 3 risk factors (Figure 2) 
(Bhatt et al 2006). Furthermore, obesity and weight gain 
appear to be among the most important determinants of the 
rate of development of hypertension and the tendency for 
other risk factors to cluster with elevated blood pressure 
(BP) (Kannel 2000a).
Although much emphasis is placed on modiﬁ  able risk fac-
tors, it is important to appreciate the impact of non-modiﬁ  able 
risk factors such as gender and age, which may inﬂ  uence 
the potency of modiﬁ  able risk factors. Increasing age plays 
an important role in the risk equation. With each additional 
year of life comes an increased risk of CVD complications, 
and the prevalence of other risk factors such as hypertension 
(Vasan et al 2002) and dyslipidemia (Primatesta and Poulter 
2000) are seen to increase. A non-smoking male aged 35–44 
with total cholesterol:high-density lipoprotein (HDL) ratio 
of 6, and a systolic BP of 150 mmHg, has a 15% risk of a 
coronary event over the next 10 years. At 45–64, bearing the 
same systolic BP and cholesterol levels (though in reality 
both may increase with age), his risk is between 15% and 
30%. At 65 years, his risk is greater than 30%. Interestingly, 
the impact of the modiﬁ  able risk factors diminishes with 
age, for example, an analysis of 10 cohort studies found 
that lowering total cholesterol by 10% was associated with 
a 54% CHD risk reduction in men aged 40 years, but only 
a 20% reduction in men aged 70 years (Figure 3) (Law et al 
1994). Taken together, these examples support the concept 
that risk factor management should be implemented early 
and aggressively to be most effective.
Epidemiological studies have demonstrated a continuum 
of risk for increasing levels of BP, total cholesterol (TC), 
low-density lipoprotein (LDL), and smoking (Wilson et al 
1998). For BP beginning at 115/75 mmHg, the risk of CVD 
doubles with each increment of 20/10 mmHg (Chobanian 
et al 2003). Similarly, the risk of CHD and CVD increases in a 
similar manner with LDL cholesterol (LDL-C) concentration 
(Neaton and Wentworth 1992; Stamler et al 1993; Thomas 
et al 2002). This has important implications for disease 
management. In an environment where some international 
guidelines still outline therapeutic cut-off points for BP and 
LDL-C, it is critical for physicians (and indeed patients) to 
understand that there is no threshold where CV risk ceases to 
exist. There is no level of risk that can be considered “safe”. 
In response to these ﬁ  ndings, target levels for LDL-C and BP 
have moved progressively downwards. This trend is set to 
continue as a number of studies have provided evidence that 
intensive lipid-lowering therapy that reduces LDL-C beyond 
the levels currently recommended is associated with reduced 
progression of coronary atherosclerosis and greater protec-
tion against death or major CV events than more moderate 
therapy (Cannon et al 2004; Nissen et al 2004a).
REACH Registrya
aBhatt et al 2006
HTN, hypertension; REACH, The Reduction of Atherothrombosis for Continued Health.
Risk factors include: treated diabetes mellitus, diabetic nephropathy, asymptomatic carotid
stenosis ≥70%, systolic blood pressure ≥150 mm Hg, treated hypercholesterolemia, current
smoking, men≥55 years, women ≥70 years.
N= 67,888
Patients aged
≥45 years from
44 countries
81.8% HTN 81.8% HTN 81.8% HTN
90.3% with 90.3% with ≥ ≥3r i s kf a c t o r s 3r i s kf a c t o r s
Figure 2 Most hypertensive patients have additional risk factors (Bhatt et al 2006).Vascular Health and Risk Management 2006:2(4) 465–475
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addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
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Another important ﬁ  nding is that the increased risk of 
CVD resulting from multiple risk factors is frequently greater 
than simply additive (Neaton and Wentworth 1992; Thomas 
et al 2002). Using data from the Multiple Risk Factor Inter-
vention Trial (MRFIT), Neaton and colleagues examined the 
interaction between TC levels, systolic BP, smoking, and 
CHD death rates (Neaton and Wentworth 1992). Figure 4 
illustrates the strong, graded relationship between increasing 
TC levels and CHD death across systolic BP levels, and the 
similarly strong relationship between increasing systolic BP 
and CHD death across TC levels. When risk factors were 
analyzed together, patients in both the highest TC and the 
highest systolic BP quintiles had an approximately 11-fold 
greater risk of CHD death than patients who were in both 
the lowest TC and lowest systolic BP quintiles (Neaton and 
Wentworth 1992). Similarly, Liao et al studied a cohort of 
more than 15,800 Americans and found that the incidence 
rate of CVD events observed in patients with hypertension 
and elevated LDL-C was 51 per 10,000 person years (Liao 
et al 2004). This was signiﬁ  cantly larger than the sum of 
the incidence rates expected due to either condition alone 
(28 per 10,000 person years). The excess risk of 31% 
indicates synergism between these two risk factors. Patho-
physiology studies have provided potential mechanisms by 
which hypertension and dyslipidemia might synergistically 
accelerate atherosclerosis, including increased endothelial 
permeability (Meyer et al 1996), increased intimal retention 
of atherogenic lipoproteins (Rakugi et al 1996), exacerba-
tion of inﬂ  ammation (Barter 2005; Bautista et al 2005), and 
increased free radical production (Rodriguez-Porcel et al 
2003); all of which may contribute to endothelial dysfunction 
(Bonetti et al 2003).
The signiﬁ  cance of the relationships between CV risk 
factors and CVD events have been elegantly demonstrated 
in the results of recent clinical trials and meta-analyses 
which have assessed the effects of intensive interventions 
Age 40 years
0- 2 0 % - 4 0 % - 6 0 %
Age 70 years
Age 50 years
CHD risk reduction in men with 10% reduction in total cholesterol
Figure 3 Inﬂ  uence of age on relationship between cholesterol and coronary heart disease (CHD) (Law et al 1994).
Figure 4 The additive effect of cholesterol and systolic blood pressure on the risk of coronary heart disease death. Reproduced with permission from Neaton JD, 
Wentworth D. 1992. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall ﬁ  ndings and differences by age for 316,099 white 
men. Multiple Risk Factor Intervention Trial Research Group.  Arch Intern Med, 152:56–64. Copyright © 1992. American Medical Association.  All rights reserved.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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aimed at reducing modiﬁ  able risk factors for CVD (Gaede 
et al 2003; Julius et al 2004; Baigent et al 2005). Based on 
a meta-analysis of clinical trials enrolling 90,056 patients 
Baigent et al concluded that, regardless of baseline LDL-C 
levels, the 5-year risk of major coronary events, coronary 
revascularization, and stroke was lowered by approximately 
20% per 1 mmol/L (38.8 mg/dL) reduction in LDL-C 
(Baigent et al 2005). Similarly, Turnbull et al demonstrated 
in a meta-analysis of randomized trials of antihypertensives 
that the relative risks of stroke and major CV events were 
signiﬁ  cantly reduced (by 28% and 22%, respectively) when 
systolic BP was lowered by an average of 5 mmHg using 
angiotensin-converting enzyme (ACE) inhibitor-based 
regimens versus placebo (Turnbull 2003). The Steno-2 
study demonstrated that in patients with type 2 diabetes and 
microalbuminuria, intensive interventions targeted at hyper-
glycemia, hypertension, dyslipidemia, and microalbuminuria, 
together with the secondary prevention of CVD using aspirin, 
could reduce the risk of CVD by 50% versus conventional 
treatment (Gaede et al 2003).
The way in which the multiple risk factors for CVD 
cluster dictates that the disease should be approached in a 
way that takes all of these risk factors into account when 
evaluating risk and when choosing the most appropriate 
treatment. Addressing only a single risk factor will reduce an 
individual’s CVD risk but leave a substantial residual risk; 
such a strategy equates to “missing” those patients who are 
at long-term risk of disease and leads to chronic sub-optimal 
management of the disease. In contrast, a population-wide 
intervention to reduce both systolic BP and TC could reduce 
CVD events by 45% (Emberson et al 2004).
Key points
–  Risk factors for CVD frequently cluster in individuals 
and can act in a synergistic manner to increase the risk 
of CV events.
–  Age is an important unmodiﬁ  able risk factor for CVD. 
With increasing age, the 10-year risk of CVD increases 
steeply.
–  There is a continuum of risk for CVD with increasing 
levels of BP, TC, LDL-C, and smoking; and this risk is 
greater still in individuals with diabetes. There is no lower 
threshold level at which CVD risk ceases to exist.
Current approach to managing 
these factors
There are numerous guidelines for the treatment and man-
agement of individual risk factors such as hypertension 
(Chobanian et al 2003; Mancia et al 2007) and dyslipidemia 
(National Cholesterol Education Program 2001), as well as 
joint guidelines for the prevention of atherosclerosis and 
CVD (De Backer et al 2003; Joint British Societies 2005). 
The mutual underlying principles of these guidelines include 
the following:
–  CV risk assessment.
–  Treatment of those at high risk for disease.
–  Management adjusted to patient’s total risk of CHD or 
CVD; the higher the risk, the greater the intensity of 
management.
–  Employment of a range of interventions to address risk 
factors for CVD, including treatment of hypertension, 
treatment of dyslipidemia, smoking cessation, increased 
physical activity, cardioprotective diet, treatment of 
hyperglycemia, weight management, antiplatelet/
anticoagulant therapy, and psychosocial support.
Considering the body of scientiﬁ  c evidence that supports 
these guidelines, the management of CVD should include all 
of these elements, as a minimum. However, the success (in 
terms of lowering CV risk) in disseminating relevant new 
clinical data and implementing treatment guidelines has in 
general been disappointing (Erhardt et al 2004). Surveys and 
observational studies continue to demonstrate that the man-
agement/control of CV risk factors is poor – even in devel-
oped countries where more resources exist for implementing 
guidelines (EUROASPIRE I and II Group 2001; Johnson et al 
2006; Wong et al 2006). The REACT survey, conducted with 
physicians from 5 European countries, showed that while 
81% of practitioners agreed with therapeutic guidelines and 
reported using them, only 18% felt that the guidelines were 
being implemented to any great extent (Hobbs and Erhardt 
2002). There are various issues that prevent guidelines from 
being implemented effectively and thus inhibit the successful 
reduction of CV risk (Table 2). A discussion paper regarding 
implementation of guidelines for CVD is provided by Erhardt 
et al (Erhardt et al 2004).
In recent years, the most relevant development in CVD 
guidelines has been the acknowledgement of the multifacto-
rial nature of CVD. Too often, the treatment focus will be on a 
single risk factor that might lower the risk by up to 20%–30%, 
however, it must be remembered that the residual risk in this 
individual is still 70%–80%; more can be done. This has 
resulted in a positive shift from management based solely 
on single risk factors, towards managing a patient’s total 
CV risk, as demonstrated by the incorporation of tools for 
calculating CV risk into recent treatment guidelines (National 
Cholesterol Education Program 2001; De Backer et al 2003; Vascular Health and Risk Management 2006:2(4) 465–475
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The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Joint British Societies 2005). However, the understanding of 
the importance of this approach has still not had far-reaching 
impact and has not been implemented in a uniform manner, 
as highlighted by the management conundrums outlined 
below, some of which have their foundations entrenched in 
the fact that CVD is a multifactorial disease.
Management conundrums
As management guidelines evolve, based on emerging clini-
cal data, they will invariably include elements of scientiﬁ  c 
evidence, practicality, consensus, and compromise. There 
will always be the inevitable challenge of bridging the gap 
between theory and practice. Today, there are a number of 
conundrums regarding the management of CVD which con-
tinue to be debated and have yet to be effectively addressed 
within current guidelines.
Population versus high-risk approach?
Two approaches to primary prevention are generally recog-
nized: the high-risk approach which involves the identiﬁ  ca-
tion and treatment of only those individuals at high risk; 
and the population approach which involves population-
wide changes in risk factors so that the entire population 
distribution of those with CVD is shifted, meaning that less 
individuals fall within the “at risk” level (Figure 5). The 
high-risk approach is the most obvious choice for those 
concerned about the CV risk of the individual patient, limit-
ing treatment to only those most likely to have a CV event 
in the short term. However, this is complicated by the fact 
that on a population basis, most CV events do not occur in 
the small number of high-risk individuals but rather in the 
much larger proportion of patients in the low-to-moderate 
risk stratum. For example, MacMahon and Rodgers found 
that 75% of strokes occur among those with “normal” BP 
levels (MacMahon and Rodgers 1994).
Consequently, if the primary focus of management is on 
treating the minority of individuals at high risk, while the 
individual patient may beneﬁ  t, the impact on national mor-
tality and morbidity ﬁ  gures will remain almost unchanged 
because intervention is only provided to a small number 
of individuals. To achieve a considerable impact on CVD 
requires an approach that serves the individual with overt dis-
ease as well as those with risk factors that predispose them to 
disease in later life. Long-term pharmaceutical drug use can 
only be justiﬁ  ed in a limited number of people. Therefore, a 
strategy that reduces the level of risk in the entire population 
is required. Hence a combination of high-risk and population 
approaches is needed. A number of advantages and disadvan-
tages of these two approaches are outlined in Table 3.
Who should be considered as high risk?
We have already determined that because of the continuum 
of risk, there is no level of CVD risk which can be con-
sidered as “safe”. In addition, advancing age confers an 
increasing risk for CVD to the patient, so the individual’s 
10-year risk is continually changing. Guidelines differ with 
Table 2 Factors that inﬂ  uence the implementation of CVD guidelines
Barrier to implementation  Examples
System-related Limited  reimbursement
 Increased  liability
 Inadequate  stafﬁ  ng resource
  Lack of specialist support
  Lack of counseling materials
Physician-related   Inadequate identiﬁ  cation of individuals at risk for CVD (De Muylder 
  et al 2004; Hobbs and Erhardt 2002)
  Inadequate counseling of patients regarding the severity of the 
  disease and the need for adequate adherence to prescribed 
  medications (Egede 2003)
  Failure to increase treatment intensity (Simpson et al 2003)
  Lack of critical evaluation of guidelines (Faergeman 1999)
  Aversion to polypharmacy
  Confusion/lack of belief in contradictory guidelines
  Inertia to changing medical practice
 Budgetary  concerns
Patient-related  Poor understanding/awareness of personal disease risk (Cabana et al 1999)
  Poor long-term adherence with lifestyle changes and poor adherence 
  with CV-risk reducing medications (Chapman et al 2005; Avorn et al 1998)
Abbreviation: CVD, cardiovascular disease.Vascular Health and Risk Management 2006:2(4) 465–475
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Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
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respect to the deﬁ  nition of high risk, depending on health 
system and health policy environments. Many currently used 
guidelines deﬁ  ne patients at high risk as those with a 30% 
absolute risk of developing a CV event within the next 10 
years. More recent guidelines have changed the deﬁ  nition 
of high risk to encompass patients with 20% risk of CV 
events (Joint British Societies 2005). The reason why these 
levels are chosen is based on a number of factors including 
scientiﬁ  c, ﬁ  nancial, practical, as well as political issues. 
However, as we have also shown, the number of patients 
that fall within this 20%–30% of risk is small. Adoption of 
20%–30% 10-year risk as an indication for therapy denies 
a huge proportion of individuals the opportunity to prevent 
or delay a ﬁ  rst vascular event, and subjects the individual 
to years of potential atherogenic damage.
Emberson et al elegantly demonstrated that with high-
risk strategies, the higher the level at which high risk is 
deﬁ  ned, the less effective the reduction in CVD levels is 
(Figure 6) (Emberson et al 2004). Furthermore, they found 
that aggressive treatment in individuals with a 10-year 
Framingham risk of 30% would theoretically reduce 
the occurrence of major CVD by approximately 11%, this 
increased to 34% when a 20% high-risk threshold was 
employed. However, when modest (10%) downshifts to the 
population distribution of serum TC and systolic BP were 
applied, a reduction in major CVD by 45% was observed 
(Emberson et al 2004).
This leads to the question of whether the deﬁ  nition of “high 
risk” used as an indicator for therapeutic intervention in guide-
lines is set too high. The answer is probably “yes”. Considering 
that CV risk factors may start to cluster early in life (Bao et al 
1994), it is essential that the risk factor burden of people in 
their second and third decades is reduced. Essentially, a shift 
is needed in the perception of those who are at risk. Many 
guidelines still focus on absolute 5-, 7-, or 10-year projec-
tions of CHD or CVD risk (National Cholesterol Education 
Program 2001; De Backer et al 2003; Joint British Societies 
2005). This may be an inadequate approach in younger or 
Figure 5 Pictorial representation of the distribution of risk for cardiovascular disease, and high-risk and population-based management strategies.
Table 3 Advantages and disadvantages of high-risk and population approaches to CVD management
 Advantages  Disadvantages
Individualized high risk approach  Easy to motivate the patient  Limited potential for impact
  Provides high risk: beneﬁ  t ratio  Weak predictive power
    More CVD cases among the large 
    numbers at low-medium risk
Population approach  Radical  Small beneﬁ  t to the individual
  Large potential beneﬁ  t for   Difﬁ  cult to motivate the patient
  impact by reducing the number of those at risk  Risk: beneﬁ  t ratio unknown
Abbreviations: CVD, cardiovascular disease.Vascular Health and Risk Management 2006:2(4) 465–475
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Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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middle-aged patients. For example, a 50-year-old man with 
high cholesterol and hypertension has a 10-year risk of heart 
attack or coronary death of only 7%, but a lifetime risk that 
is 10-times greater (Lloyd-Jones et al 2006).
Ideally, what is needed is a longer – preferably life-
time – risk assessment in order that interventions can be 
applied in time to prevent underlying vascular events. 
However, the level ﬁ  nally chosen to delineate high risk will 
ultimately be a decision based on cost, ie, what level of risk 
can affordably be managed on a large scale. Hence, while 
scientiﬁ  c knowledge will continue to promote reducing the 
level that constitutes high risk, lack of funding and political 
arguments will continue to promote maintaining the level at 
that which is affordable.
Relative or absolute risk?
Knowledge of the multifactorial nature of CVD has prompted 
the development of management systems based on “absolute 
risk” of developing CVD. Absolute risk – the actual odds 
that a patient (or population) will develop an event over a 
given period of time – reﬂ  ects the sum of all the factors that 
contribute to the risk of CVD. Absolute risk always increases 
with advancing age, irrespective of the level of BP, cholesterol, 
or of smoking habits. This measurement is useful in that it 
allows identiﬁ  cation of individuals who need to be advised 
immediately about risk factor reduction. However “relative 
risk” measurements can also be a useful tool for clinicians, 
particularly in younger patients with a low absolute risk, 
because they can provide information regarding who is at 
a high relative risk compared with their peers and who may 
beneﬁ  t from aggressive risk factor reduction in the long term. 
The recently updated ESH-ESC guidelines recommend that 
treatment of younger patients should be based on their rela-
tive risk rather than their absolute risk (Mancia et al 2007). 
These updated preventive guidelines also contain relative risk 
scores for younger individuals to facilitate the understanding 
of risk in these individuals who have a low absolute 10-year 
risk of CVD events.
Conversely, when formulating public health policy abso-
lute risk reductions should be used as these provide a far more 
meaningful measure of what can be achieved at the population 
level. For example, reducing the daily salt intake from 9.5 g to 
6 g will lead to a 13% reduction in stroke and a 10% reduction 
in heart disease (Medical Research Council 2006).
Cardiovascular risk calculators are available that measure 
either absolute or relative risk, so it will be interesting to observe 
whether the useful information that can be derived from both 
of these measurements will be used to its fullest in the future.
Key points
–  CVD guidelines have evolved to take account of the 
multifactorial nature of CVD, resulting in management 
strategies centered on lowering a patient’s total CV risk.
–  Implementation of CVD guidelines is poor.
–  To achieve a considerable impact on CVD requires a 
management approach that serves the individual with 
risk factors that predispose them to disease in later life 
as well as those with overt disease.
Figure 6 The impact of different levels of Framingham-predicted 10-year risk of cardiovascular disease (CVD) on the percentage reduction of CVD and the proportion 
of patients treated. Reproduced with permission from Emberson J, Whincup P, Morris RW, et al 2004. Evaluating the impact of population and high-risk strategies for the 
primary prevention of cardiovascular disease. Eur Heart J, 25:484–91. Copyright © Oxford University Press.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Recommended optimal approach
Based on the issues discussed above, the following represents 
our attempt at outlining what the optimal approach to CVD 
management might involve. While we accept that practicali-
ties may always lie in the way of achieving what is essentially 
an idealistic approach, an appreciation of appropriate goals is 
an important step in improving management practices.
Step 1: Identifying patients at risk/
estimating level of total lifetime risk
Recognizing patients who are at risk of a CV event is the ﬁ  rst 
step to achieving effective prevention. Patients with existing 
CVD are usually at high risk for recurrent CVD events, but 
healthy patients with multiple CV risk factors may be as likely 
to suffer a CVD event as those with clinically manifest disease. 
It is a particularly important step for those with existing CV 
risk factors, as other CV risk factors likely coexist. When one 
CV risk factor has been identiﬁ  ed, especially hypertension, 
regular screening for other CV risk factors is desirable.
Indeed, it can be argued that the concepts of primary and 
secondary prevention are now obsolete (Plummer 2006). 
Firstly, as mentioned above, apparently healthy individuals 
with no previous CV events, may have asymptomatic 
indications of CVD, such as carotid artery stenosis and left 
ventricular hypertrophy, and thus may be at higher risk than 
those who have had CV events. Secondly, a patient may be 
unaware that they have had a CV event and thus if treatment 
recommendations are based on the occurrence of a CV event 
rather than their risk of a future event such patients would 
be managed inappropriately. For example, approximately 
20% of MIs were unrecognized in the Atherosclerosis Risk 
in Communities (ARIC) study (Boland et al 2002).
Considering the many variables that need to be considered 
in calculating an individual’s risk for CVD, it is essential that 
a properly validated risk assessment tool be used to help the 
physician derive an accurate picture of the individual’s risk. 
Effective risk assessment tools estimating absolute CV risk 
are available and should be used to identify people at high risk 
for CVD. They should be considered an aid to making clinical 
decisions about how intensively to intervene on lifestyle 
and how to proceed with the use of antihypertensive, lipid-
lowering, and other modiﬁ  able risk factor medications. There 
are many variables that confer risk which are not included in 
the common risk algorithms – dietary and exercise habits, and 
psychosocial factors – and therefore any risk assessment must 
be individualized and include these factors. Furthermore, a 
positive family history and diabetes mellitus, not included in 
most risk algorithms, increases the risk of CVD signiﬁ  cantly. 
Consequently, risk assessment tools are never exact and 
should be used in combination with clinical judgment.
In recent years web-based systems, score card methods, 
and tools such as the “Grimm Meter” have become available 
and have simpliﬁ  ed the risk assessment procedure (Thomsen 
et al 2001; Conroy et al 2003; Gohlke et al 2005; Grimm and 
Svendsen 2006). Many risk assessment tools are available 
that are of beneﬁ  t in particular patient populations. A detailed 
review of these methods is outside the scope of this review 
(see Grover et al 2006 for a recent review).
The decision over which risk assessment tool to employ is 
somewhat less important than the choice to actually use a risk 
assessment tool. As most tools generally arrive at a similar 
estimation of risk, the actual tool chosen is probably not 
critical. However, it is essential that some form of risk assess-
ment is used as this leads to improved estimation of patient 
risk and hence better management. A study by Backlund 
et al demonstrated that physicians often underestimate their 
patients CV risk (Figure 7) (Backlund et al 2004), and other 
studies show that physicians rarely or never use tools when 
calculating a patient’s CVD risk (Hobbs and Erhardt 2002; 
De Muylder et al 2004). Hobbs and Erhardt showed that 43% 
of physicians reported that they never use risk calculator 
charts that may accompany guidelines, a further 43% said 
they sometimes referred to them, but only 13% said that this 
was always the case (Hobbs and Erhardt 2002).
There are some important caveats to using risk assessment 
tools. First, it is important for clinicians to appreciate that 
such tools provide only an estimate of risk. Biologic variabil-
ity might mean that someone with a very low risk score could 
experience a CV event and someone with a very high chance 
of experiencing an event may not. Second, the outcome of 
the risk scoring exercise may not be the only reason why a 
physician may choose to offer an intervention; clinical judg-
ment and thorough individual assessment (including exercise 
habits, food habits, and psychosocial factors) also need to 
play a role. Third, risk evaluation alone does not provide 
adequate information to help the patient understand their own 
risk and begin to make steps towards improving their own 
modiﬁ  able risk factor status. There are many physician- and 
patient-related barriers to communications regarding risk, 
an understanding of which is important for fully utilizing 
information arising from risk evaluation measures. Fourth, 
without improving therapeutic intervention, risk scoring is 
of little use. As Zimmerman and Horton-La Forge noted in 
1996, “little evidence exists to suggest that risk assessment 
alone, without more intensive intervention, can have a lasting Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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impact on health behaviors or health risks” (Zimmerman and 
Horton-La Forge 1996).
Step 2: Helping the patient to understand 
their personal risk
Providing patients with their CVD risk score is a useful means 
of motivating patients towards healthy behaviors (Sullivan et al 
2004; Alm-Roijer et al 2006). An understanding of both the 
fatal consequences and also the potential debilitating effects 
of nonfatal CV events, such as MI or stroke, may encourage 
patients to adhere to CV medications and life-style changes. 
However, this may be a little simplistic because uninformed 
patients may have difﬁ  culty in understanding the concepts of 
risk (Knapp et al 2004). Knapp et al found that the use of verbal 
descriptors to improve the level of information about side-effect 
risk leads to overestimation of the level of harm and may lead 
patients to make inappropriate decisions about whether or not 
they take the medicine (Knapp et al 2004). It is difﬁ  cult, then, 
for the physician to decide what information to provide about 
CV risk. As a guide, physicians might wish to consider the 
following areas for communication with their patients:
Probability: Focus on the relative risk faced by that par-
ticular patient. Patients with CHD beneﬁ  t from having speciﬁ  c 
individualized knowledge about their condition and their own 
risk factor status for promoting adherence to lifestyle changes 
and medical treatment (Alm-Roijer et al 2006);
Exposure: Communicate that everyone faces the risk 
of CVD;
Hazard: Emphasize the modifiable risk factors the 
patient can control;
Consequences: Create a mental picture of CVD events, 
without creating fear, because this can inﬂ  uence whether 
a patient takes prescribed medications (Knapp et al 2004). 
Within this concept, it is important to reiterate the need for 
adherence to both lifestyle changes and medications. Previ-
ous studies have clearly demonstrated that the percentage of 
patients who are adherent to both antihypertensive and lipid-
lowering therapies declines sharply within the ﬁ  rst year of 
therapy initiation (Chapman et al 2005). Furthermore, a link 
between low adherence to CV medications and poor clinical 
outcome has been demonstrated in a variety of settings (Wei 
et al 2002; Ho et al 2006a, b).
Considering the challenges associated with establishing 
and maintaining effective communication with the CVD 
patient, and the consequences faced when this is not effec-
tively achieved, it is likely that utilizing other healthcare 
professionals in the provision of in-depth counseling could 
be an advantage. With this in mind, the Risk Evaluation 
and Communication Health Outcomes and Utilization Trial 
(REACH OUT) has recently been completed. The study 
will assess the ability of a physician-delivered CHD risk 
evaluation and communication program to lower a patient’s 
predicted 10-year risk of MI or death due to CHD by 10% 
within 6 months, compared with usual care. Results from this 
trial are anticipated towards the later part of 2007. The results 
of this study promise to be of great interest to all of those 
involved in managing patients with CVD.
Step 3: Developing a comprehensive 
management strategy for the
individual patient
An effective management strategy for CVD should contain 
some element of lifestyle modiﬁ  cation as well as pharma-
ceutical intervention, where appropriate (Figure 8). As a ﬁ  rst 
Figure 7 Physicians underestimation of their patients’ cardiovascular risk (Backlund et al 2004)Vascular Health and Risk Management 2006:2(4) 465–475
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(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
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step in the management of their overall CVD risk, patients 
should be encouraged to adhere to healthy lifestyle habits. 
Patients should be informed of the beneﬁ  ts of smoking ces-
sation, exercise, diet modiﬁ  cation, and weight loss. A recent 
study supports this concept and has indicated that as many as 
62% of CV events in men are preventable through adopting 
a low-risk lifestyle (Chiuve et al 2006). Compared with men 
who did not make lifestyle changes during follow-up in this 
study, those who adopted 2 additional low-risk lifestyle 
factors had a 27% lower risk of CHD (Chiuve et al 2006).
Where lifestyle changes are insufficient, therapy is 
advised. This should include a range of interventions such 
as treatment of hypertension, dyslipidemia, hyperglycemia, 
and antiplatelet/anticoagulant therapy.
It is important that the physician and patient closely col-
laborate to develop a management strategy that will suit the 
individual patient. One study showed that a multidimensional 
integrative approach, which identiﬁ  ed speciﬁ  c health behav-
iors important for each patient to modify, was able to signiﬁ  -
cantly reduce the risk of CVD. The patient, together with a 
health coach and a medical provider, devised a personal health 
plan which was driven not only by CV risk reduction but also 
the interests of the patient. Techniques used to help implement 
the health plan included meditation, relaxation training, stress 
management, motivational techniques, and health education 
and coaching (Edelman et al 2006). It has been suggested that 
by working together, a goal-setting effort between patient and 
physician/medical team – if employed and adhered to – can 
help reduce CV risk (MacGregor et al 2006).
Given the multifactorial nature of CVD it is not surprising 
that clinical trials have consistently demonstrated that multiple 
CV risk factors should be managed simultaneously to maxi-
mize reductions in CV events (Samuelsson et al 1987; Sever 
et al 2003). The downside to this approach is that increasing 
pill burden and prescription costs can decrease adherence 
to treatment (Chapman et al 2005; Safran et al 2005; Lynch 
2006; Soumerai et al 2006). Consequently, the development 
of multi-modal drugs, which in a single pill can target a num-
ber of risk factors, is a promising approach. In 2003, Wald 
and Law introduced the concept of combining medicines 
for effective risk factor reduction by use of the Polypill™. 
They proposed that a single, daily pill containing half doses 
(to minimize toxicity) of a beta-blocker, a thiazide diuretic, 
an ACE inhibitor, a statin, folic acid, and aspirin, taken by 
everyone aged 55 could reduce the incidence of CVD by 
more than 80% (Wald and Law 2003).
Figure 8 Comprehensive management strategy for patients with cardiovascular disease risk factors.Vascular Health and Risk Management 2006:2(4) 465–475
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The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Step 4: Providing continued follow-up 
support
The aims of patient follow-up support should be to assess 
and communicate to the patient the success of intervention 
strategies in order to i) maintain patient motivation, ii) 
identify problems in adherence to the disease management 
strategy (there is a very real difference between obtaining 
a prescription for a medication and actually taking it), iii) 
provide further disease/therapy information.
Follow-up studies have observed that educational pro-
grams and counseling on CV risk and events have a signiﬁ  cant 
effect for up to 12 months (Barth et al 2006) and demonstrate 
the need for continued counseling and follow-up support. 
However, more information needs to be made available to the 
physician/medical team to help them provide such follow-up 
support effectively. Support should also be provided to those 
who have had a debilitating CV event such as an MI or stroke, 
who frequently live for many years after such an event.
Key points
–  Recognizing patients who are at risk of a CV event is the 
ﬁ  rst step to achieving effective CVD prevention.
–  The concepts of primary and secondary prevention are 
in many ways now obsolete and should be substituted by 
proper risk calculation and risk stratiﬁ  cation.
–  Properly validated risk assessment tools should be used 
to help derive an accurate picture of the patient’s total 
CV risk, but should be used in conjunction with clinical 
judgment.
–  Advising patients of their CVD risk is a useful means of 
motivating patients towards healthy behaviors, but needs 
to be done sensitively because the concept of risk can be 
misunderstood.
–  Management for CVD should entail a close collaboration 
between the physician, other healthcare professionals, 
and the patient to develop a strategy that will suit the 
individual patient. It should include elements of lifestyle 
modiﬁ  cation as well as pharmaceutical intervention, 
where appropriate, to address the multiple CV risk factors 
likely to be present. Follow-up support should be pro-
vided to ensure patient adherence and provide additional 
support where necessary.
Providing optimal care
in a resource-scarce environment
Although the recommended optimal approach discussed 
above would bring about a substantial reduction in the 
prevalence of CVD, we need to be realistic considering the 
strong ﬁ  nancial constraints under which many healthcare 
systems are operating. Indeed, 80% of the total global 
burden of CVD is carried by countries of low/moderate 
income (WHO 2005). Disease prevention with statins and 
antihypertensive therapy has been shown to be cost-effective 
as the morbidity and mortality reductions and increases in 
life expectancy can be considerable (McMurray 1999; Pilote 
et al 2005). Nonetheless, further research is needed to acquire 
knowledge of the long-term cost consequences of various 
treatments and interventions. Cost-effective interventions 
to reduce the burden of CVD can only be implemented if 
health services policy environments and ﬁ  nancial resources 
allow. For many (if not most) countries, the individual man-
agement of large numbers of patients, outside the high-risk 
sphere for CVD, will simply not be affordable. So what can 
be done to maximize any management efforts that are made 
in such countries?
Other healthcare providers
Implementation of a medical team approach in dealing with 
the patient’s needs is likely to be a more effective strategy 
than heavy reliance on the physician. Nurse-led care-share 
programs have been shown to be successful in providing the 
additional support and health promotion needed for effective 
management of CVD. Also, nurse evaluation of CV risk and 
medication adherence prior to and/or following the physician 
visit may help reinforce messages surrounding the importance 
of the illness and the need to adhere to prescribed therapies and 
lifestyle changes; and often patients ﬁ  nd it easier to discuss 
such issues with a nurse. One UK study compared intensive 
management by nurses with routine follow-up in general prac-
tice for patients with CHD. Patients who received intensive 
nurse-led care reported improvements in their health, func-
tional status, and in the likelihood of hospitalization within the 
ﬁ  rst year of care (Campbell et al 1998). In the USA, nurse case 
managers help in the care of patients in the out-patient set-
ting. Their role includes securing long-term patient adherence 
and follow-up; developing clinic policy and computerized 
patient databases, and implementing management according 
to established CHD guidelines (Thomas et al 1997).
Care programs such as those described above are likely 
to be critical in improving care within any environment, but 
particularly those with limited resources. The most effective 
way of optimizing the outlay spent on managing CVD is to 
ensure that treatment applied is appropriate, that the patient 
adheres to the treatment and that, ultimately, risk factors for 
the disease are controlled.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Key points
–  Providing optimal care for CVD is challenging consid-
ering the strong ﬁ  nancial constraints under which many 
healthcare systems are operating.
–  The most effective way of optimizing the outlay spent 
on managing CVD is to ensure that the treatment applied 
is appropriate, that the patient adheres to the prescribed 
treatment and that, ultimately, risk factors for CVD are 
controlled.
–  The implementation of an effective nurse-patient interac-
tion may improve the CV management.
What can we hope for in the future?
Guidelines relevant to CVD continue to evolve and improve. 
Signiﬁ  cant advances were made in recent Canadian guide-
lines, on a number of levels, ie, by including global estimates 
of patient’s risk, by providing guidance on improving patient 
treatment adherence, and by improving the way in which the 
guidelines are disseminated and implemented (Drouin et al 
2006; Khan et al 2006). The Canadian Hypertension Edu-
cation Program (CHEP) recognizes that annually-updated, 
evidence-based guidelines for hypertension alone are not 
sufﬁ  cient to improve the management of hypertension in 
Canada and have thus included an Implementation Task 
Force whose role it is to enhance dissemination and imple-
mentation of hypertension guidelines. Considering the impact 
that CHEP may have had on improvements in the manage-
ment of hypertension in Canada, it is possible that it may 
serve as a model for disease management recommendations 
(Drouin et al 2006).
The recently updated ESH-ESC guidelines (Mancia et al 
2007) will also help to reinforce key messages; the guidelines 
emphasize the importance of assessing total CV risk, imple-
mentation of life-style changes, and blood pressure reduction 
per se rather than the antihypertensive class selected. In 
addition, the new guidelines recommend that combination 
therapy should be considered from the start (the choice of 
drug should be based on patient comorbidities), the threshold 
for initiating treatment should be more ﬂ  exible (140/90 mm 
Hg), and that all high-risk hypertensive patients (those with 
diabetes, multiple risk factors, or organ damage) should aim 
for a BP goal of 130/80 mm Hg. Moreover, it is noted that 
absolute risk should be used to guide treatment in the elderly 
whereas relative risk should be used in younger patients.
In future years, we might also expect to see improvements 
in risk assessment models and algorithms which measure 
global lifetime risk for CVD and improve existing models 
by adding novel risk factors. However, while the search for 
novel risk factors continues, any discoveries in this area are 
likely to be less important than the more thorough imple-
mentation of existing risk tools that are based on established 
risk factors. This is because 80% of CVD risk is conveyed 
by the 3 major risk factors: smoking, elevated BP, and high 
serum TC (Emberson et al 2003). With optimal control of 
these risk factors, signiﬁ  cant reduction in CV events may 
be obtained.
As explained earlier, the concept of a compound that can 
target multiple risk factors is likely to be an important tool 
for CVD management. While considerable challenges are 
likely to be faced in developing a therapy with the optimistic 
number of components proposed by Wald and Law (2003), 
inroads are being made with the development of combination 
therapies for CVD (Blank et al 2005).
Ultimately, preventing an epidemic of CVD will likely 
require a combination of both medical and public health 
approaches. Public health strategies that target whole popula-
tions may offer a great prospect for reducing CVD.
Key points
–  In future years, we might expect guidelines for CVD to 
evolve further by including elements to further help the 
patient adhere to prescribed treatment regimens and by 
including estimates of a patient’s global CV risk. Improv-
ing the dissemination and implementation of guidelines 
is likely to be vital in improving the control of CV risk 
factors.
–  Compounds that target multiple risk factors for CVD may 
improve patient adherence.
–  Ultimately, preventing an epidemic of CVD will likely 
require a combination of both medical and public health 
approaches.
Conclusion
The management of CVD is currently far from optimal, even 
in parts of the world with well-developed and well-funded 
healthcare systems. This is particularly concerning when 
considering the huge increase in CVD in low-middle income 
countries where healthcare systems are not funded to manage 
the growing CV epidemic.
The continued movement away from the treatment of 
individual CV risk factors to managing overall and lifetime 
CV risk is likely to have a signiﬁ  cant impact on blunting 
the projected increase in CVD. However, for this to become 
effective, the importance of this approach needs to be appreci-
ated on an even greater scale and ingrained into every aspect 
of CVD management.Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
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most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Managing cardiovascular risk in practice
A broad range of extremely effective lifestyle, counsel-
ing, and therapeutic interventions can be used in conjunc-
tion with CV risk assessment tools to markedly reduce an 
individual’s risk of CVD. Ultimately, however, quelling 
the CVD epidemic is likely to require a combination of 
effectively managing those at high risk of disease, and 
optimizing widespread population interventions which aim 
to reduce the number of individuals at risk. Considering the 
huge consequences of falling short in these aims, the suc-
cess (or otherwise) in implementing these elements will be 
scrutinized.
Acknowledgments
Editorial assistance was provided by Jon Edwards of Envision 
Pharma and funded by Pﬁ  zer Inc.
References
Alm-Roijer C, Fridlund B, Stagmo M, et al. 2006. Knowing your risk factors 
for coronary heart disease improves adherence to advice on lifestyle 
changes and medication. J Cardiovasc Nursing, 21:E24–E31.
[AHA] American Heart Association. 2003. International cardiovascular 
disease statistics. Dallas, Texas: American Heart Association.
Ansell BJ. 2005. Evidence for a combined approach to the management of 
hypertension and dyslipidemia. Am J Hypertens, 18:1249–57.
Asmar R, Vol S, Pannier B, et al. 2001. High blood pressure and associated 
cardiovascular risk factors in France. J Hypertens, 19:1727–32.
Avorn J, Monette J, Lacour A, et al. 1998. Persistence of use of lipid-
lowering medications:a cross-national study. JAMA, 279:1458–62.
Backlund L, Bring J, Strender J-E, et al. 2004. How accurately do general 
practitioners and students estimate coronary risk in hypercholester-
olaemic patients. Primary Health Care Research and Development, 
5:145–52.
Baigent C, Keech A, Kearney PM, et al. 2005. Efﬁ  cacy and safety of choles-
terol-lowering treatment: prospective meta-analysis of data from 90,056 
participants in 14 randomised trials of statins. Lancet, 366:1267–78.
Bao W, Srinivasan SR, Wattigney WA, et al. 1994. Persistence of multiple 
cardiovascular risk clustering related to syndrome X from childhood 
to young adulthood. The Bogalusa Heart Study. Arch Intern Med, 
154:1842–7.
Barter P. 2005. The inﬂ  ammation: lipoprotein cycle. Atheroscler Suppl, 
6:15–20.
Barth J, Critchley J, Bengel J, et al. 2006. Efﬁ  cacy of psychosocial interven-
tions for smoking cessation in patients with coronary heart disease:a 
systematic review and meta-analysis. Ann Behav Med, 32:10–20.
Bautista LE, Vera LM, Arenas IA, et al. 2005. Independent association 
between inﬂ  ammatory markers (C-reactive protein, interleukin-6, 
and TNF-alpha) and essential hypertension. J Hum Hypertens, 
19:149–54.
Bhatt DL, Steg PG, Ohman EM, et al. 2006. International prevalence, 
recognition, and treatment of cardiovascular risk factors in outpatients 
with atherothrombosis. JAMA, 295:180–9.
Blank R, LaSalle J, Reeves R, et al. 2005. Single-pill therapy in the treatment 
of concomitant hypertension and dyslipidemia (The Amlodipine/Ator-
vastatin Gemini Study). J Clin Hypertens, 7:264–73.
Boland LL, Folsom AR, Sorlie PD, et a. 2002. Occurrence of unrecognized 
myocardial infarction in subjects aged 45 to 65 years (the ARIC study). 
Am J Cardiol, 90:927–31.
Bonetti PO, Lerman LO, Lerman A, et al. 2003. Endothelial dysfunc-
tion: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol, 
23:168–75.
Booth GL, Kapral MK, Fung K, et al. 2006. Relation between age and 
cardiovascular disease in men and women with diabetes compared 
with non-diabetic people: a population-based retrospective cohort 
study. Lancet, 368:29–36.
Cabana MD, Rand CS, Powe NR, et al. 1999. Why don’t physicians follow 
clinical practice guidelines? A framework for improvement. JAMA, 
282:1458–65.
Campbell NC, Thain J, Deans HG, et al. 1998. Secondary prevention clin-
ics for coronary heart disease: randomized trial of effect on health. 
BMJ, 316:1434–7.
Cannon CP, Braunwald MD, McCabe CH, et al. 2004. Intensive and mode-
rate lipid lowering with statins after acute coronary symptoms. N Engl 
J Med, 350:1495–504.
Chapman RH, Benner JS, Petrilla AA, et al. 2005. Predictors of adherence 
with antihypertensive and lipid-lowering therapy. Arch Intern Med, 
165:1147–52.
Chiuve SE, McCullough ML, Sacks FM, et al. 2006. Healthy lifestyle fac-
tors in the primary prevention of coronary heart disease among men. 
Circulation, 114:160–7.
Chobanian AV, Bakris GL, Black HR, et al. 2003. The seventh report 
of the joint national committee on prevention, detection, evaluation, 
and treatment of high blood pressure: The JNC 7 Report. JAMA, 
289:2560–72.
Conroy RM, Pyorala K, Fitzgerald AP, et al. 2003. Estimation of ten-year 
risk of fatal cardiovascular disease in Europe: the SCORE project. Eur 
Heart J, 24:987–1003.
De Backer G, Ambrosioni E, Borch-Johnsen K, et al. 2003. European 
guidelines on cardiovascular disease prevention in clinical practice. 
Third Joint Task Force of European and Other Societies on Car-
diovascular Disease Prevention in Clinical Practice. Eur Heart J, 
24:1601–10.
De Muylder R, Lorant V, Paulus D, et al. 2004. Obstacles to cardiovascular 
prevention in general practice. Acta Cardiol, 59:119–25.
Drouin D, Campbell NR, Kaczorowski J, et al. 2006. Implementation of 
recommendations on hypertension: the Canadian Hypertension Educa-
tion Program. Can J Cardiol, 22:595–8.
Edelman D, Oddone EZ, Liebowitz RS, et al. 2006. A multidimensional 
integrative medicine intervention to improve cardiovascular risk. J Gen 
Intern Med, 21:728–34.
Egede LE. 2003. Implementing behavioral counseling interventions in 
primary care to modify cardiovascular risk in adults with diabetes. 
Cardiovasc Rev Rep, 24:306–12.
Emberson JR, Whincup PH, Morris RW, et al. 2003. Reassessing the contri-
bution of serum total cholesterol, blood pressure and cigarette smoking 
to the aetiology of coronary heart disease: impact of regression dilution 
bias. Eur Heart J, 24:1719–26.
Emberson J, Whincup P, Morris RW, et al. 2004. Evaluating the impact 
of population and high-risk strategies for The primary prevention of 
cardiovascular disease. Eur Heart J, 25:484–91.
Erhardt LR, Pearson TA, Bruckert E, et al. 2004. Guidelines and their 
implementation: a discussion document focused on the best appraches 
to drive improvement. Vascular Disease Prevention, 1:1667–74.
EUROASPIRE I and II Group. 2001. Clinical reality of coronary prevention 
guidelines:a comparison of EUROASPIRE I and II in nine countries. 
EUROASPIRE I and II Group. European Action on Secondary Preven-
tion by Intervention to Reduce Events. Lancet, 357:995–1001.
Faergeman O. 1999. Challenges to best practice: Why are guidelines not 
implemented. Eur Heart J Suppl, 1(Suppl J):J12–J17.
Felmeden DC, Spencer CG, Blann AD, et al. 2003. Low-density lipopro-
tein subfractions and cardiovascular risk in hypertension: relationship 
to endothelial dysfunction and effects of treatment. Hypertension, 
41:528–33.
Gaede P, Vedel P, Larsen N, et al. 2003. Multifactorial intervention and 
cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 
348:383–93.
Giles TD, Berk BC, Black HR, et al. 2005. Expanding the deﬁ  nition and 
classiﬁ  cation of hypertension. J Clin Hypertens, 7:505–12.Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
Coronary artery disease in women: a review
on prevention, pathophysiology, diagnosis, and
treatment
A
u
t
h
o
r
 
c
o
p
y
 
o
n
l
y
Vascular Health and Risk Management 2007:3(5) 602
Erhardt et al
Gohlke HK, Winter M, Karoff M, et al. 2005. CARRISMA: a new tool 
to optimize cardiovascular risk management in primary prevention 
[abstract]. Circulation, 12:3794 (Abstract).
Greenland P, Knoll MD, Stamler J, et al. 2003. Major risk factors as ante-
cedents of fatal and nonfatal coronary heart disease events. JAMA, 
290:891–7.
Grimm R Jnr, Svendsen K. 2006. Cardiovascular risk meter: A device for 
rapid estimation of cardiovascular disease mortality in clinical settings. 
J Clin Hypertens, 8(Suppl A 5) [abstract]:A236 (P-577, MP-55).
Grover SA, Hemmelgarn B, Joseph L, et al. 2006. The role of global risk 
assessment in hypertension therapy. Can J Cardiol, 22:606–13.
Haffner SM, Lehto S, Ronnemaa T, et al. 1998. Mortality from coronary 
heart disease in subjects with type 2 diabetes and in nondiabetic 
subjects with and without prior myocardial infarction. N Engl J Med, 
339:229–34.
Ho PM, Rumsfeld JS, Masoudi FA, et al. 2006a. Effect of medication 
nonadherence on hospitalization and mortality among patients with 
diabetes mellitus. Arch Intern Med, 166:1836–41.
Ho PM, Spertus JA, Masoudi FA, et al. 2006b. Impact of medication therapy 
discontinuation on mortality after myocardial infarction. Arch Intern 
Med, 166:1842–7.
Hobbs FD, Erhardt L. 2002. Acceptance of guideline recommendations and 
perceived implementation of coronary heart disease prevention among 
primary care physicians in ﬁ  ve European countries: the Reassessing 
European Attitudes about Cardiovascular Treatment (REACT) survey. 
Fam Pract, 19:596–604.
Huxley R, Barzi F, Woodward M. 2006. Excess of fatal coronary heart 
disease associated with diabetes in men and women: meta-analysis of 
37 prospective cohort studies. BMJ, 332:73–8.
International Diabetes Federation. Diabetes Atlas, 3rd ed. [online]. URL: 
http://www.eatlas.idf.org/media/
Jackson R, Lawes CM, Bennett DA, et al. 2005. Treatment with drugs to 
lower blood pressure and blood cholesterol based on an individual’s 
absolute cardiovascular risk. Lancet, 365:434–41.
Johnson ML, Pietz K, Battleman DS, et al. 2006. Therapeutic goal attainment 
in patients with hypertension and dyslipidemia. Med Care, 44:39–46.
Joint British Societies 2005. JBS 2: Joint British Societies’ guidelines 
on prevention of cardiovascular disease in clinical practice. Heart, 
91(Suppl 5):v1–v52.
Julius S, Kjeldsen SE, Weber M, et al. 2004. Outcomes in hypertensive 
patients at high cardiovascular risk treated with regimens based 
on valsartan or amlodipine: the VALUE randomised trial. Lancet, 
363:2022–31.
Kannel WB. 2000a. Fifty years of Framingham Study contributions to 
understanding hypertension. J Hum Hypertens, 14:83–90.
Kannel WB. 2000b. Risk stratiﬁ  cation in hypertension: new insights from 
the Framingham Study. Am J Hypertens, 13:3S–10S.
Khan NA, McAlister FA, Rabkin SW, et al. 2006. The 2006 Canadian 
hypertension education program recommendations for the management 
of hypertension: Part II – Therapy. Can J Cardiol, 22:583–93.
Knapp P, Raynor DK, Berry DC, et al. 2004. Comparison of two methods 
of presenting risk information to patients about the side effects of 
medicines. Qual Saf Health Care, 13:176–80.
Law MR, Wald NJ, Thompson SG. 1994. By how much and how quickly 
does reduction in serum cholesterol concentration lower risk of isch-
aemic heart disease. BMJ, 308:367–72.
Lerner DJ, Kannel WB. 1986. Patterns of coronary heart disease morbid-
ity and mortality in the sexes: a 26-year follow-up of the Framingham 
population. Am Heart J, 111:383–90.
Liao D, Mo J, Duan Y, et al. 2004. The joint effect of hypertension and 
elevated LDL-cholesterol on CHD is beyond additive. Eur Heart J, 
25(abstract suppl):235[abstract #1377].
Lloyd-Jones DM, Leip EP, Larson MG, et al. 2006. Prediction of lifetime 
risk for cardiovascular disease by risk factor burden at 50 years of age. 
Circulation, 113:791–8.
Lynch T. 2006. Medication costs as a primary cause of nonadherence in the 
elderly. Consult Pharm, 21:143–6.
MacGregor K, Handley M, Wong S, et al. 2006. Behavior-change action 
plans in primary care: a feasibility study of clinicians. J Am Board 
Fam Med, 19:215–23.
MacMahon S, Rodgers A. 1994. Blood pressure, antihypertensive treatment 
and stroke risk. J Hypertens Suppl, 12:S5–S14.
McManus B. 2005. INTERHEART: nine factors that could save your life. 
Healthc Q, 8:28.
McMurray J. 1999. The health economics of the treatment of hyperlipidemia 
and hypertension. Am J Hypertens, 12:99S–104S.
Mancia G. 2006. Total cardiovascular risk:a new treatment concept. 
J Hypertens Suppl, 24:S17–S24.
Mancia G, De Backer G, Dominiczak A, et al. 2007. 2007 Guidelines for 
the Management of Arterial Hypertension: The Task Force for the 
Management of Arterial Hypertension of the European Society of 
Hypertension (ESH) and of the European Society of Cardiology (ESC). 
J Hypertens, 25:1105–87.
Medical Research Council. 2006. Why 6g? A summary of the scientiﬁ  c 
evidence for the salt intake target. Cambridge: Medical Research 
Council.
Meyer G, Merval R, Tedgui A, et al. 1996. Effects of pressure-induced 
stretch and convection on low-density lipoprotein and albumin uptake 
in the rabbit aortic wall. Circ Res, 79:532–40.
Murray CJ, Lopez AD 1997. Alternative projections of mortality and dis-
ability by cause 1990–2020: Global Burden of Disease Study. Lancet, 
349:1498–504.
Natarajan S, Liao Y, Cao G, et al. 2003. Sex differences in risk for coro-
nary heart disease mortality associated with diabetes and established 
coronary heart disease. Arch Intern Med, 163:1735–40.
National Cholesterol Education Program. 2001. Executive Summary of The 
Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cho-
lesterol In Adults (Adult Treatment Panel III). JAMA, 285:2486–97.
Neaton JD, Wentworth D. 1992. Serum cholesterol, blood pressure, cigarette 
smoking, and death from coronary heart disease. Overall ﬁ  ndings and 
differences by age for 316,099 white men. Multiple Risk Factor Inter-
vention Trial Research Group. Arch Intern Med, 152:56–64.
Nissen SE, Tuzcu EM, Schoenhagen P, et al. 2004. Effect of intensive com-
pared with moderate lipid-lowering therapy on progression of coronary 
atherosclerosis:a randomized controlled trial. JAMA, 291:1071–80.
O’Meara JG, Kardia SL, Armon JJ, et al. 2004. Ethnic and sex differences 
in the prevalence, treatment, and control of dyslipidemia among hyper-
tensive adults in the GENOA study. Arch Intern Med, 164:1313–18.
Pilote L, Ho V, Lavoie F, et al. 2005. Cost-effectiveness of lipid-lowering 
treatment according to lipid level. Can J Cardiol, 21:681–7.
Plummer CJ. 2006. What’s in the CARDS. Diab Med, 23:711–14.
Primatesta P, Poulter NR. 2000. Lipid concentrations and the use of lipid 
lowering drugs:evidence from a national cross sectional survey. BMJ, 
321:1322–5.
Puska P, ed. 1988. Comprehensive cardiovascular community control pro-
grammes in Europe. Copenhagen: WHO Regional Ofﬁ  ce for Europe 
(EURO Reports and Studies 106).
Puska P, Vartiainen E, Tuomilehto J, et al. 1998. Changes in premature 
deaths in Finland:successful long-term prevention of cardiovascular 
diseases. Bull World Health Organ, 76:419–25.
Rakugi H, Yu H, Kamitani A, et al. 1996. Links between hypertension and 
myocardial infarction. Am Heart J, 132:213–21.
Rayner M. 2000. European Cardiovascular Disease Statistics.
Reaven GM, Lithell H, Landsberg L, et al. 1996. Hypertension and associ-
ated metabolic abnormalities – the role of insulin resistance and the 
sympathoadrenal system. N Engl J Med, 334:374–81.
Rodriguez-Porcel M, Lerman LO, Herrmann J, et al. 2003. Hypercholesterol-
emia and hypertension have synergistic deleterious effects on coronary 
endothelial function. Arterioscler Thromb Vasc Biol, 23:885–91.
Rosamond W, Flegal K, Friday G, et al. 2007. Heart disease and stroke 
statistics–2007 update:a report from the American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee. Circulation, 
115:e69–e171.Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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